Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)

The ASTRIDE trial in first-line ES-SCLC reported favorable median overall survival with serplulimab plus chemotherapy versus atezolizumab plus chemotherapy. The study enrolled more than 200 U.S. patients, including people from underrepresented racial and ethnic populations; the supplied article excerpt gives no survival figures or statistical details.